Industry | 2019.09.12
Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that professor David Schaffer has been appointed to the advisory board of the company’s biologics business. Dr. Schaffer has played an integral advisory role on the gene therapy industry, as Catalent has moved into gene therapy services through the company’s May 2019 $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.
(PRWeb September 12, 2019)
Read the full story at https://www.prweb.com/releases/catalent_announces_the_appointment_of_david_schaffer_to_biologics_advisory_board/prweb16569042.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]visory_board/prweb16569042.htm
